Glargine-treated patients do not show higher cancer risk

07/29/2013 | MedPage Today (free registration)

A study in Diabetes Care showed patients who began treatment with insulin glargine had a nonsignificant 12% higher cancer incidence at one year compared with those on human neutral protamine Hagedorn insulin. Researchers also found women on glargine therapy for more than two years did not have a higher risk of breast cancer than those on NPH, while glargine-treated men had a nonsignificant 2.66-fold increased risk of prostate cancer at 12 to 24 months compared with the NPH group.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC